Healthcare (SH:603313)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥2,143,312,803.14, representing a year-on-year increase of 13.46%[5] - The net profit attributable to shareholders for Q1 2022 was ¥30,822,292.14, showing a decline of 44.23% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,802,896.08, an increase of 48.13% year-on-year[5] - The basic earnings per share for Q1 2022 was ¥0.06, down 60.00% from the previous year[5] - The weighted average return on equity was 1.06%, a decrease of 0.48 percentage points compared to the previous year[5] - Total operating revenue for Q1 2022 was ¥2,143,312,803.14, an increase of 13.4% compared to ¥1,889,004,260.53 in Q1 2021[28] - Net profit for Q1 2022 was ¥35,398,174.00, a decrease of 46.0% from ¥65,540,471.37 in Q1 2021[32] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.06, down from CNY 0.15 in Q1 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,185,841,492.70, a slight decrease of 0.14% from the end of the previous year[8] - The equity attributable to shareholders at the end of the reporting period was ¥2,921,454,832.16, an increase of 0.50% from the previous year[8] - The company's total liabilities decreased slightly to ¥6,171,311,975.43 from ¥6,204,638,697.98 year-over-year[28] - The total liabilities of the company increased, reflecting a need for careful management of financial obligations[19] Cash Flow - The net cash flow from operating activities was -¥107,088,289.77, reflecting a year-on-year increase of 7.44%[5] - Cash inflow from operating activities totaled CNY 2,235,418,738.81, an increase from CNY 1,970,532,516.12 in the previous year[34] - Total cash outflow from operating activities was CNY 2,342,507,028.58, an increase from CNY 2,086,231,878.21 in Q1 2021[34] - The ending balance of cash and cash equivalents was CNY 608,589,835.27, down from CNY 864,365,807.82 at the end of Q1 2021[35] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,301[13] - The largest shareholder, Ni Zhanggen, holds 49.27% of the shares, with 127,526,068 shares pledged[13] Investments and Expenses - The company has made significant investments in fixed assets, totaling RMB 2,371,342,706.56, although this represents a slight decrease from the previous period[23] - Research and development expenses for Q1 2022 were ¥27,016,719.14, down from ¥30,456,850.43 in Q1 2021, indicating a reduction of 11.9%[28] - The company reported a decrease in other comprehensive income, with a net amount of -¥14,689,873.38 for Q1 2022 compared to -¥22,104,249.50 in Q1 2021[32] - The company’s financial expenses increased to ¥65,361,104.51 in Q1 2022 from ¥47,796,643.92 in Q1 2021, reflecting a rise of 36.8%[28] Accounts Receivable and Inventory - Accounts receivable increased to RMB 1,313,860,387.11, up from RMB 1,125,245,842.66, indicating a growth of about 16.7%[19] - The company's inventory stood at RMB 1,986,237,138.59, slightly up from RMB 1,939,131,042.06, reflecting an increase of approximately 2.4%[23] Legal and Financial Risks - The company reported a provision for bad debts of USD 1,232,079.56 related to accounts receivable from a subsidiary, indicating potential financial risks[18] - The company is involved in ongoing litigation with a minority shareholder, with potential liabilities amounting to USD 1,850.72 million, which could impact future financial performance[18]